Vector Quality Control

Characterization of gene therapy drug products to determine vector identity, quantify impurities, and assess replication competence, minimizes risk for patients in clinical trials and beyond. At GeneWerk, we provide the full spectrum of assays for vector quality control in line with current FDA and EMA regulatory guidelines.

Unbiased and comprehensive assessment of drug products

Early understanding of vector quality attributes, right from pre-clinical development, will help reduce costs and accelerate timelines. Our end-to-end services for vector quality control link findings from different stages of development – from pre-clinical to clinical – to gain an early and comprehensive understanding of the drug product.

At GeneWerk, we combine powerful NGS-based techniques with streamlined bioinformatics analysis to provide a complete picture of vector quality and safety.

Our comprehensive service portfolio includes sample preparation, library preparation, next-generation sequencing, bioinformatics analysis and reporting.

AAVSEQ

Adeno-associated virus sequencing (AAVSEQ) is an NGS-based approach to identify and quantify residual nucleic acid impurities and analyze AAV genome identity and integrity in pre-clinical and clinical AAV preparations.

  • Comprehensive AAV vector quality and safety assessment
  • Cost efficient solution overcoming PCR-related biases
  • Analysis reports tailored to your unique therapy and regulatory requirements
Read more about AAVSEQ

LENTISEQ

Lentivirus sequencing (LENTISEQ) is a similar NGS-based approach to identify and quantify residual nucleic acid impurities, including genome identity confirmation, in pre-clinical and clinical retroviral preparations.

  • Comprehensive retroviral vector quality and safety assessment
  • Cost-efficient solution overcoming PCR-related biases
  • Analysis reports tailored to your unique therapy and regulatory requirements
Read more about LENTISEQ

Want to get in touch?

Consult with our experts about solutions to your biosafety challenges.

Contact us

Latest news

Read our latest press releases and announcements below.

Protagen Protein Services merges with GeneWerk

Protagen Protein Services (PPS) today announced that it will merge with GeneWerk, an Ampersand...

Read More

GeneWerk Announces Growth Equity Investment from Ampersand…

GeneWerk will expand capabilities to meet rapidly growing demand for cell and gene therapy...

Read More

Insight into Spatial and Temporal Trends of…

Genewerk GmbH in collaboration with University Heidelberg Germany provided an insight into spatial and...

Read More

GeneWerk in the Holiday Park

A little fun for everyone! This year’s company trip took us to the Holiday...

Read More
I agree to the Privacy Policy and Terms of Service.